Preparation of novel S-allyl cysteine chitosan based nanoparticles for use in ischemic brain treatment

Objective : To enhance the brain bioavailability of S -allyl- l -cysteine (SC) by developing novel S -allyl- l -cysteine chitosan nanoparticles (SC CS NPs) and examining the quantity of SC by developing a novel method of ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) in ischemic rat brain treatment. Methods : The ionotropic gelation method was used to develop S -allyl cysteine-loaded CS NPs. The 4-factor, 5-level central composite design was optimized to determine the effect of independent variables, i.e. , particle size, polydispersity index (PDI), zeta potential, EE, and loading capacity, together with their characterization, followed by drug release and intranasal permeation to enhance the brain bioavailability and examination of their neurobehavioral and biochemical parameters with their histopathological examination. Results : SC CS NPs were optimized at the particle size of 93.21 ± 3.31 nm (PDI: 0.317 ± 0.003), zeta potential of 44.4 ± 2.93, and drug loading of 41.23 ± 1.97% with an entrapment efficiency of 82.61 ± 4.93% having sustain and controlled release (79.92 ± 3.86%) with great permeation (>80.0%) of SC. SC showed the retention time of 1.021 min and 162.50/73.05 m / z . SC showed good linearity in the range of 5.0-1300.0 ng mL −1 , % inter-and-intraday accuracy of 96.00-99.06% and CV of 4.38-4.38%. We observed significant results, i.e. , p < 0.001 for improved (AUC) 0-24 and C max delivered via i.v. and i.n. dose. We also observed the highly significantly observations of SC CS NPs (i.n.) based on their treatment results for the biochemical, neurobehavioral, and histopathological examination in the developed ischemic MCAO brain rat model. Conclusion : The excellent significant role of mucoadhesive CS NPs of SC was proven based on the enhancement in the brain bioavailability of SC via i.n. delivery in rats and easy targeting of the brain for ischemic brain treatment followed by an improvement in neuroprotection based on a very small dose of SC. Enhancing the brain bioavailability of S -allyl- l -cysteine (SC) by developing novel S -allyl- l -cysteine chitosan nanoparticles and examining the quantity of SC by developing a novel method of ultra-high performance liquid chromatography-tandem mass spectrometry in ischemic rat brain treatment.